World of DTC Marketing
FEBRUARY 25, 2021
According to the AMA one of the key reasons for non-adherence is that patients may be frightened of potential side effects. Additionally, patients report not taking their medication because they may have witnessed side effects experienced by a friend or family member who was taking the same or similar medication.
World of DTC Marketing
FEBRUARY 4, 2021
As early as 2009, Merck knew of more than 200 reports of depression, including suicidal thoughts, in men taking Propecia, according to an internal “risk management” assessment from that year. Food and Drug Administration (FDA) is meant to help patients and warn of potential drug side effects but a Vice report indicates something more.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 28, 2022
Ceftobiprole was turned down by the FDA in 2009 for ABSSSI, when the drug was partnered with Johnson & Johnson’s Janssen Cilag unit. in the daptomycin-based therapy group, with no significant differences between the therapies on the overall rate of side effects. The overall success rate was 69.8%
Pharmaceutical Technology
JULY 29, 2022
Abilify (aripiprazole) , marketed by Bristol Myers Squibb and Otsuka Pharmaceuticals, was approved in 2009 for irritability treatment in six to 17-year-old children with ASD. Generic versions of both drugs are now available.
European Pharmaceutical Review
JANUARY 25, 2024
They detail the medication’s intended use, proper administration, potential side effects and precautions. They are vital to ensuring the safe and effective use of medicines, making them an integral part of healthcare in Europe. Article 63 EMA (29 January 2020). Article 63 Euractiv (26 September 2023).
Pharma Marketing Network
MARCH 25, 2023
This type of advertising is crucial in promoting new drugs and informing healthcare professionals about their benefits and potential side effects. “The Effectiveness of Direct-to-Consumer Advertising in the Pharmaceutical Industry.” ” Pharmacy and Therapeutics, 2009.
European Pharmaceutical Review
SEPTEMBER 22, 2023
While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience. Lowe SL, Duggan Evans C, et al.
Expert insights. Personalized for you.
173 
Let's personalize your content